Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC devices

This article was originally published in The Tan Sheet

Executive Summary

Ear, Nose & Throat Devices Panel will meet jointly with the Dental Products Panel of the Medical Devices Advisory Committee on Oct. 6 to "discuss general issues surrounding the prescription use versus over-the-counter use of devices intended to treat snoring or mild to severe obstructive sleep apnea (OSA)," FDA announces in an Aug. 18 Federal Register notice. Panelists will pay special attention to "the ability of the patient to self diagnose and treat OSA [and] the types of clinical data that would be needed to support an OTC intended use." Between 8 am and 8:30, the meeting will be closed to the public; from 8:30 am to 5:30 pm, the public can sit in at the Hilton Washington DC North/Gaithersburg...





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts